- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07718802
Observational Approach Versus Surgical Intervention for Stones (OASIS)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
A critical barrier to improving the health of the nearly 40 million Americans with kidney stone disease is the weak evidence base supporting the management of individuals with asymptomatic kidney stones. The proposed Observational Approach versus Surgical Intervention for Asymptomatic Stone (OASIS) randomized clinical trial answers the research question of whether observation or upfront surgery results in less life disruption from asymptomatic kidney stones for children and adults. The management options for patients with asymptomatic stones are 1) observation or 2) upfront surgical treatment, both of which are considered safe, part of usual care, widely accessible, and covered by insurance.
OASIS responds to the charge for well-designed Randomized Controlled Trials (RCT) from the Agency for Healthcare Research and Quality (AHRQ) systematic review on kidney stone disease management and ensures patient centeredness by examining outcomes that patients have identified as meaningful.
Intervention
Randomization to either:
- Observation is the surveillance of asymptomatic stones with periodic CT, ultrasound, or x-ray, and clinic visits.
- Upfront surgery is the planned removal of asymptomatic stones and includes ureteroscopy (URS) and shockwave lithotripsy (SWL), which are routinely used in standard clinical care.
Observational Cohort (Non-Randomized Cohort):
Up to 300 eligible subjects who are willing to consent to data collection but refuse randomization will be enrolled and followed for two years.
Study Design OASIS is a pragmatic randomized controlled superiority trial conducted at approximately 30 sites that participate in Patient Centered Outcomes Research Network (PCORnet). The trial will include an additional observational cohort for eligible subjects who decline randomization.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Rebecca D McCune, BS, MS
- Telefonnummer: 267-909-6030
- E-post: mccuner@chop.edu
Studer Kontakt Backup
- Navn: Brian J Augelli, BS
- Telefonnummer: 609-504-4908
- E-post: augellib@chop.edu
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- The Children's Hospital of Philadelphia
-
Hovedetterforsker:
- Gregory E Tasian, MD, MSc, MSCE
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Individuals age 6 or older
- Diagnosis of kidney stone disease (nephrolithiasis)
Asymptomatic, non-obstructive kidney stones measuring 4 to 10 mm (inclusive)
- Asymptomatic is defined as the absence of abdominal pain, flank pain, gross hematuria, and nausea and/or vomiting in the last 3 months that in the judgement of the site PI could be attributable to kidney stones.
- Non-obstructive is defined as a stone in a renal calyx or stones in multiple renal calyces on CT, ultrasound, and/or x-ray obtained within 6 months of screening.
- Informed consent and if appropriate, child assent.
- Willingness to be randomized to surgery or observation Note: subjects otherwise eligible who decline randomization may be enrolled in a parallel observational cohort.
- Fluent in English or Spanish
- Willingness to be audio- and/or video- recorded during interviews
Exclusion Criteria:
- Untreated hydronephrosis or caliectasis
- Pain (e.g., renal colic, abdominal pain) or gross hematuria attributed to kidney stones.
- Recurrent symptomatic urinary tract infections (≥3 in 12 months or ≥2 in 6 months). A symptomatic urinary tract infection is defined as having at least one bladder or voiding symptom (e.g., frequency, urgency, dysuria) with bacteriuria (≥105 colony forming units/mL of no more than 2 urinary tract pathogens).
- Stone in the renal pelvis, ureter, bladder or urethra
- Pregnant females
- Solitary kidney, transplant kidney, urinary diversion, medullary sponge kidney
- Anatomic abnormality of the kidney (e.g., horseshoe kidney)
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Non-Randomized (Observational)
|
Upfront surgery is the planned removal of asymptomatic stones and includes ureteroscopy and shockwave lithotripsy, which are routinely used in standard clinical care.
Observation is the surveillance of asymptomatic stones with periodic CT, ultrasound, or x-ray, and clinic visits.
|
|
Aktiv komparator: Randomized
|
Upfront surgery is the planned removal of asymptomatic stones and includes ureteroscopy and shockwave lithotripsy, which are routinely used in standard clinical care.
Observation is the surveillance of asymptomatic stones with periodic CT, ultrasound, or x-ray, and clinic visits.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Healthcare-related life disruption
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Composite of: Stone-specific emergency department (ED)/urgent care visits, stone-specific hospitalizations and surgery for stones for new symptoms (Shockwave Lithotripsy (SWL) and Ureteroscopy (URS)) as reported via Patient Centered Outcomes Research Network (PCORnet) Common Data Model (CDM) query and participant self-report on REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient reported physical and emotional health (Pain Interference)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference (PI) is a standardized, self-reported assessment tool developed by the National Institutes of Health (NIH).
It measures how much pain hinders a person's physical, mental, social, and recreational activities, as well as their sleep and enjoyment of life.
It uses a standardized T-score (average is 50; standard deviation is 10) to reflect the level of disruption.
Higher numbers mean more pain interference (pain is having a greater negative impact on your daily life, making it harder to participate in work, social, and physical activities).
The study team is using the validated versions for adults (18 years and older at time of consent), children (ages 8-17 years at time of consent), and parent-proxy versions for caregivers of children ages (6-7 years at time of consent).
This information will be captured via patient report in REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
|
Patient reported physical and emotional health (Anxiety)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety is a standardized, self-reported assessment tool developed by the National Institutes of Health (NIH).
It measures the severity of fear, worry, dread, hyperarousal, and physical stress symptoms over the past seven days on a 5-point scale (ranging from never to always).
Raw scores are converted into a standardized T-score with an average of 50 and a standard deviation of 10.
A higher T-score indicates a higher severity of anxiety.
The study team is using validated versions for adults (18 years and older at time of consent), children (ages 8-17 years at time of consent), and parent-proxy versions for caregivers of children ages (6-7 years at time of consent).
This information will be captured via patient report in REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
|
Patient reported physical and emotional health (Stone Quality of Life)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
The Wisconsin Stone Quality of Life questionnaire (WISQOL) is a disease-specific health-related quality of life (HRQOL) instrument designed to assess the impact on patients of stones in the urinary tract.
Each item is scored on a 5-point Likert scale, yielding a total raw score of 28 to 140.
Higher scores reflect a better health-related quality of life.
Raw scores are typically converted to a standardized 0-100 scale.
This information will be captured via patient report on REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
|
Stone passage
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months. Reporting total after 2 years.
|
Patient Reported Survey: Number of self-reported stone passages (A kidney stone episode is passing a stone that caused pain or other bothersome symptoms or having surgery to remove a stone.)
This information will be captured via patient report on REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months. Reporting total after 2 years.
|
|
Lost productivity (Missed School)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Patient Reported Survey: Number of days the patient (for patients under 18 years old at time of consent) missed school due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, more than 10 days) in the last 3 months.
This information will be captured via patient report in REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
|
Lost productivity (Caregiver Missed Work)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Patient Reported Survey: Number of days the patient's caregiver(s) (for patients <18 years old at time of consent) missed work due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, more than 10 days) in the last 3 months.
This information will be captured via patient report on REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
|
Lost productivity (Patient Missed Work)
Tidsramme: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Patient Reported Survey: Number of days the patient missed work (for patients 18 years and older at time of consent) due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, More than 10 days) in the last 3 months.
This information will be captured via patient report in REDCap.
|
Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Gregory E Tasian, MD, MSc, MSCE, Children's Hospital of Philadelphia
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Calculi
- Patologiske tilstander, anatomiske
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Urolithiasis
- Urinkalkuli
- Patologiske tilstander, tegn og symptomer
- Nyreberegning
- Nefrolitiasis
- Undersøkelsesteknikker
- Metoder
- Observasjon
- Kirurgiske prosedyrer, operativ
Andre studie-ID-numre
- 26-024242
- BPS-2025C1-44653 (Annen identifikator: Patient-Centered Outcomes Research Institute)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nefrolitiasis
-
University of British ColumbiaRekruttering
-
University of Texas Southwestern Medical CenterFullførtNephrolithiasis, urinsyreForente stater
-
Mahidol UniversityHar ikke rekruttert ennåSikkerhetsproblemer | Kirurgi-komplikasjoner | Nephrolithiasis Staghorn CalculusThailand
-
Assiut UniversityHar ikke rekruttert ennåNephrolithiasis, Glomerulonephritis, Amyloidosis, AKI, CKD, Tubuli Interstitial | Urinsystemets lidelser hos IBD-pasienter
Kliniske studier på Surgery
-
Anhui Provincial Cancer HospitalAnhui Provincial HospitalRekruttering
-
Sohag UniversityHar ikke rekruttert ennåExotropia like eller mer enn 50 prisme diopter
-
Yifan DengHar ikke rekruttert ennåERCP | Pediatrisk kirurgi | Stenting av bukspyttkjertelen | Kirurgi i tidlig barndom
-
Diakonessenhuis, UtrechtRekrutteringLivskvalitet | Søvnapné, obstruktivNederland
-
Saglik Bilimleri UniversitesiFullførtNasal obstruksjon septal avvik kompensatorisk inferior turbinat hypertrofiTyrkia (Türkiye)
-
Royal Surrey County Hospital NHS Foundation TrustUkjentEggstokkreft | Egglederkreft | Peritoneal kreft | Neoplasma i eggstokkene | Ovarial neoplasma epitelialStorbritannia
-
University of Colorado, DenverRekrutteringForbedret restitusjon etter operasjon | Gynekologisk sykdomForente stater
-
ARCAGY/ GINECO GROUPFullførtEggstokkreft stadium IIIC | Eggstokkreft Stadium IV | Eggstokkreft stadium IIIbFrankrike
-
National Taiwan University HospitalIntuitive SurgicalRekrutteringKolelithiasis | CholedocholithiasisTaiwan
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteFullført